Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

  • Nynke GL Jager1Email author,
  • Rutger HT Koornstra2,
  • Andrew D Vincent3,
  • Ron HN van Schaik4,
  • Alwin DR Huitema1,
  • Tiny M Korse5,
  • Jan HM Schellens6, 7,
  • Sabine C Linn2, 8 and
  • Jos H Beijnen1, 7
Contributed equally
BMC Cancer201313:612

https://doi.org/10.1186/1471-2407-13-612

Received: 6 March 2013

Accepted: 16 December 2013

Published: 28 December 2013

Abstract

Background

Tamoxifen has dramatically reduced the recurrence and mortality rate of estrogen receptor positive breast cancer. However, the efficacy of tamoxifen varies between individuals and 40% of patients will have a recurrence despite adjuvant tamoxifen treatment. Factors that predict tamoxifen efficacy would be helpful for optimizing treatment. Serum concentrations of the active metabolite, endoxifen, may be positively related to treatment outcome. In addition, hot flashes are suggested to be positively associated with tamoxifen treatment outcome.

Methods

We investigated in a series of 109 patients whether the frequency and severity of hot flashes were related to concentrations of tamoxifen and its metabolites. A serum sample of all patients was analyzed for the concentration of tamoxifen, N-desmethyltamoxifen, endoxifen and 4-hydroxytamoxifen, as well as for estradiol concentrations and several single nucleotide polymorphisms in CYP2D6. Additionally, these patients completed a questionnaire concerning biometric data and treatment side effects.

Results

We found no evidence supporting an association between concentrations of tamoxifen or metabolites and either the frequency or severity of hot flashes in the covariate unadjusted analyses. However, including interactions with menopausal status and pre-treatment hot flash (PTHF) history indicated that post-menopausal women with PTHF experienced an increasing frequency of hot flashes with increasing serum concentrations of tamoxifen and its metabolites. This finding was not altered when adjusting for potential confounding factors (duration of tamoxifen treatment, CYP2D6 phenotype, estradiol serum concentration, age and body mass index). In addition we observed a positive association between body mass index and both hot flash frequency (p = 0.04) and severity (p < 0.0001). We also observed that patients with lower estradiol levels reported more severe hot flashes (p = 0.02).

Conclusions

No univariate associations were observed between concentrations of active tamoxifen metabolites and either the frequency or severity of hot flashes during treatment. However, the frequency of hot flashes may be exacerbated by higher serum concentrations of tamoxifen and its metabolites in post-menopausal women with a history of hot flashes prior to tamoxifen treatment.

Keywords

EndoxifenTamoxifenHot flashesEstrogen levelsCYP2D6Breast cancer

Background

For over 30 years tamoxifen, a selective estrogen receptor (ER) modulator, has been the standard treatment for estrogen receptor positive breast cancer patients, in both the adjuvant and metastatic setting. Tamoxifen has dramatically reduced the recurrence and mortality rate for patients with ER + breast cancer [1]. However, as many as 40% of patients receiving adjuvant tamoxifen and almost all patients with metastatic disease eventually relapse and die from the disease [2]. Due to this high percentage of patients with an apparent lack of benefit, identification of early predictors of outcome of tamoxifen treatment may be helpful in the optimization of the treatment [3].

Tamoxifen itself is considered to be a prodrug that is converted into many metabolites. The metabolites with the highest therapeutic activity are 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen (endoxifen), binding 100-fold more potent to the ER than tamoxifen itself [4]. The antiestrogenic activities of endoxifen and 4-hydroxytamoxifen are similar, although endoxifen, unlike 4-hydroxytamoxifen, also inhibits aromatase and is present at higher steady state concentrations in patients than 4-hydroxytamoxifen [47]. Recently, Madlensky et al. reported that low endoxifen levels are associated with worse outcome after tamoxifen treatment, suggesting that there is a minimum threshold serum level of endoxifen that when exceeded lowers the recurrence rate [8]. However, assays for routine measurement of concentrations of tamoxifen and its metabolites are not generally available in daily practice. Therefore, the quest for other biomarkers for treatment efficacy is still ongoing.

Tamoxifen is metabolized by cytochrome P450 (CYP) enzymes, in which the formation of endoxifen predominantly depends on CYP2D6. Inactivating genetic polymorphisms in CYP2D6 have been associated with lower endoxifen levels [911] and consequently CYP2D6 genotype has been suggested as a potentially useful marker for the prediction of treatment outcome. Recently, the ATAC and the BIG1-98 studies concluded that genetic variants of CYP2D6 are not predictive for outcome in tamoxifen-treated patients [12, 13], although the validity of these findings has been questioned [14].

The occurrence of side effects, such as hot flashes, is a potential biomarker for treatment outcome, analogous to what has been described with EGFR inhibitors and skin-toxicity [15]. It is known that breast cancer patients treated with tamoxifen suffer more frequently from hot flashes, compared to placebo-treated breast cancer patients [16]. The severity of hot flashes is suggested to increase during the first three months of tamoxifen treatment, followed by a plateau or even a decrease for the duration of treatment [17, 18].

Mortimer et al. showed that the occurrence of hot flashes is positively related to outcome after tamoxifen treatment [19]. Cuzick et al. investigated whether the occurrence of treatment-related symptoms (vasomotor symptoms or joint symptoms) is associated with breast cancer recurrence. They found a trend that patients using tamoxifen who experienced newly emergent vasomotor symptoms (e.g. hot flushes, night sweats and cold sweats) had a lower recurrence rate, although these results were not statistically significant [20].

Recently, Lorizio et al. reported that the serum concentration of endoxifen is positively associated with the probability of reporting any side effect from tamoxifen (hot flashes, vaginal dryness, sleep problems, weight gain, and depression, irritability or mood swings combining all side effects and grades). When focusing on hot flashes only, this association was not statistically significant. Irvin et al. performed a genotyped tamoxifen dose-escalation study and found no correlation between endoxifen concentrations and the extent to which patients were bothered by hot flashes, neither at baseline nor at four months after dose escalation [10].

In order to clarify whether there is an association between concentrations of tamoxifen and its main metabolites and either frequency or severity of hot flashes, we investigated a series of 109 patients treated with tamoxifen, taking into account potentially influencing factors such as menopausal status, pre-treatment hot flashes, duration of tamoxifen treatment, CYP2D6 phenotype, estradiol serum concentrations, age and body mass index (BMI).

Methods

Patients, both pre- and postmenopausal, who used tamoxifen for at least two months at the moment serum concentrations of tamoxifen and metabolites were determined as part of routine clinical care were eligible for this study. Retrospectively, these patients were asked whether they would be willing to complete a single, short questionnaire (Additional file 1) concerning biometric data and the side effects they had experienced. The questionnaire was sent to the patients along with an informative letter, stating the goal of this study and explicitly giving the patients the option to opt-out, by returning the questionnaire without filling it out. By this questionnaire, patients were asked if they had been experiencing hot flashes prior to beginning tamoxifen treatment, and also if they experienced hot flashes during tamoxifen treatment (around the time the blood sample was drawn). In both cases the patients were asked to record the frequency of the flashes per week and the average severity of the experienced hot flashes (severity categories: mild, <5 minute duration; moderate, 5 to 15 minute duration; severe, 15 to 20 minute duration; very severe, >20 minute duration). These definitions were based on the methodology and instruments for conducting hot flash studies [21, 22].

We performed this observational study with a simple, single questionnaire according to the national act on Ethics Committees (Dutch Act on medical research involving humans, February 26, 1998) and in compliance with Good Clinical Practice guidelines [23]. As a further interpretation of these GCP guidelines there is the “code of conduct of Human Tissue and Medical Research: Code of conduct for responsible use (2011)” by the Federa (http://www.federa.org/codes-conduct). In this code of conduct is stated that anonymous left-over body material may be used in observational clinical trials without explicit consent of the individual patients.

Serum sample handling and determination of tamoxifen and metabolites

The serum samples were collected in serum gel tubes and stored at -70°C for some weeks, in order to analyze more patient samples during one HPLC-MS analysis. Patient samples, calibration standards and quality control samples were handled according to the method described by Teunissen et al.[24]. The liquid chromatography – tandem mass spectrometry (LC-MS/MS) method developed by Teunissen et al.[24] was slightly modified and used for the determination of tamoxifen (5 to 500 ng/mL), N-desmethyltamoxifen (10 to 1000 ng/mL), (E)-endoxifen (1 to 100 ng/mL), (Z)-endoxifen (1 to 100 ng/mL), N-desmethyl-4′-hydroxytamoxifen (1 to 100 ng/mL), 4-hydroxytamoxifen (0.4 to 40 ng/mL) and 4′-hydroxytamoxifen (0.4 to 40 ng/mL). Detection was performed on a triple-quadrupole MS/MS detector with an electrospray ionization source (API4000, AB Sciex, Foster City, USA) operating in the positive ion mode. A partial validation was executed and all requirements for acceptance, as defined in the FDA and EMA guidelines on bioanalytical method validation [25, 26] were fulfilled.

Genotyping and predicted phenotype

DNA was isolated from 200 μL serum that was left over from the tamoxifen and metabolite analysis, using the MagNA Pure LC Total Nucleic Acid Isolation Kit I and the automated MagNA PureTM LC system (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s manual.

Genotyping was performed according to Standard Operating Procedures, using assays that were validated by direct sequencing. In each run, positive and negative controls were included. All patients were genotyped for CYP2D6*3, *4, *6 and *41 variant alleles, which will identify 95% of CYP2D6 poor metabolizers (PMs) using Taqman allelic discrimination assays with primers and probes designed by Applied Biosystems (Carlsbad, California, USA), as described earlier [27]. Polymerase chain reactions (PCR) were carried out in a reaction volume of 10 μl, containing 1 ng genomic DNA. The thermal profile consisted of an initial denaturation step at 95°C for 15 minutes, followed by 40 cycles of denaturation at 92°C for 15 seconds and 1 minute at 60°C for annealing and extension. Genotypes were scored through measuring allele-specific fluorescence using the SDS 2.2.2 software for allelic discrimination (Applied Biosystems).

On the basis of CYP2D6 genotype patients were classified into three predicted phenotype groups. Patients without nonfunctional alleles (CYP2D6*3, *4 or *6) were defined as extensive metabolizers (EMs). Intermediate metabolizers (IMs) consisted of patients that (i) carry CYP2D6*41 alleles either homozygous or in combination with a nonfunctional allele or (ii) were heterozygous for the CYP2D6*3, *4, *6 allele (*3/wt, *4/wt or *6/wt). Patients were classified as PM in case of two nonfunctional alleles (CYP2D6*3/*3, *3/*4 or *4/*4).

Estradiol concentration

The estradiol concentration was measured in the left over serum sample on a Modular Analytics E170 immunoassay analyzer, using the electrochemiluminescence technique (Roche Diagnostics), routinely used in the Netherlands Cancer Institute.

Statistical methods

The relation between hot flashes and several factors was investigated, where the serum concentrations of tamoxifen and three of its main metabolites (N-desmethyltamoxifen, endoxifen and 4-hydroxytamoxifen) were considered of primary interest. In addition there were seven secondary factors that may have a potential role confounding role: menopausal status, a history of hot flashes prior to tamoxifen treatment, duration of tamoxifen treatment, estradiol serum concentration, age, BMI and CYP2D6 predicted phenotype. The association between all factors and menopausal status was assessed using Mann–Whitney-Wilcox, Fisher exact and linear-by-linear tests as appropriate. Spearman’s rho was used to assess pairwise covariate associations between the four primary factors (tamoxifen and metabolite serum concentrations), age, BMI and estradiol concentration. Linear by linear trend tests were used to assess the association between CYP2D6 phenotype and the four primary factors. Kruskal-Wallis tests was used to determine if the four factors differed due to menopausal status and pre-treatment hot flash history. The association between reported hot flash frequency and both primary and secondary factors was assessed using over-dispersed Poisson models, both unadjusted (univariable) and multivariable regressions. Similarly, the association between all factors and the severity of hot flashes was assessed using proportional-odds ordinal regressions. It was assumed that these associations may be influenced by menopausal status and the occurrence of pre-tamoxifen treatment hot flashes (PTHF). Due to the small number of pre-menopausal women reporting PTHF the influence of menopausal status and PTHF was assessed via pair-wise interactions with a three level menopausal and pre-treatment hot flash status variable (pre-menopausal versus post-menopausal & PTHF versus post-menopausal & no PTHF). In the multivariable analyses, estradiol concentrations were log transformed and missing estradiol and CYP2D6 values due to insufficient material were imputed with population medians. Due to the large number of individuals missing for the CYP2D6 assessments, sensitivity analyses were performed; once with these individuals imputed as poor-intermediate metabolizers and once excluding these individuals. For samples with an estradiol concentration level below the lower limit of quantitation (43 pmol/L), half of the lower limit of detection (21.5 pmol/L) was imputed. The level of significance for all tests was set at 0.05. The analysis was performed using the R (v3.0.1) using package MASS for ordinal regression and coin for linear by linear tests (http://cran.r-project.org/).

Results

Cohort

Between July 2008 and December 2011 serum samples from 165 patients treated with tamoxifen at the Netherlands Cancer Institute, Amsterdam, the Netherlands were obtained and analyzed for tamoxifen and metabolite concentrations. These 165 patients received the questionnaire. 33 patients did not respond to the questionnaire that was sent and 13 patients returned the reply form empty, thereby choosing the option to opt-out and not participate in this study. In total, 119 patients returned a filled out questionnaire, of which 115 forms were correctly completed. Six patients were excluded for the following reasons: one patient had an uncertain menopausal status at the moment of blood sampling; one patient was taking medication to relieve menopausal complaints; it turned out that two patients used tamoxifen less than two months at the moment of blood sampling and two patients used tamoxifen for distant metastases for an exceptionally long time (over 6 years). In total, 109 patients (all female, age mean (range) 51 years (22–76)) were enrolled in the study. The patients were divided into two groups, based on menopausal status. Table 1 presents an overview of patient characteristics.
Table 1

Patient characteristics

Characteristics

Total cohort

Pre-menopausal

Post-menopausal

p-value

 

n = 109

n = 56

n = 53

 

n (%)

n (%)

n (%)

Median age at assessment (years)

51

45

58

<0.0001

   Range

22 - 76

22-54

40 - 76

 

Median Body Mass Index

24

24

24

0.44

   Range

17 - 43

17 - 34

18 - 29

 

T-status (TNM)

   

0.73

   T1

48 (44%)

23 (41%)

25 (47%)

 

   T2

27 (25%)

16 (29%)

11 (21%)

 

   T3

2 (1.8%)

1 (1.8%)

1 (1.9%)

 

   Unknown

32 (29%)

16 (29%)

16 (30%)

 

N-status (TNM)

   

1.00

   N0

45 (41%)

24 (43%)

21 (40%)

 

   N+

49 (45%)

26 (46%)

23 (43%)

 

   Unknown

15 (14%)

6 (11%)

9 (17%)

 

AJCC stage (7th ed.)

   

0.87

   Stage I

26 (24%)

14 (25%)

12 (23%)

 

   Stage IIa

32 (29%)

16 (29%)

16 (30%)

 

   Stage IIb

7 (6%)

5 (9%)

2 (4%)

 

   Stage IIIa

9 (8%)

4 (7%)

5 (9%)

 

   Stage IIIb

0

0

0

 

   Stage IIIc

6 (6%)

3 (5%)

3 (6%)

 

   Unknown

29 (27%)

14 (25%)

15 (28%)

 

Estrogen receptor

   

NA

   Positive

93 (85%)

50 (89%)

43 (81%)

 

   Unknown

16 (15%)

6 (11%)

10 (19%)

 

Progesterone receptor

   

1.00

   Positive

10 (9%)

5 (9%)

5 (9%)

 

   Negative

83 (76%)

45 (80%)

38 (72%)

 

   Unknown

16 (15%)

6 (11%)

10 (19%)

 

HER2 status

   

1.00

   Positive

38 (35%)

20 (36%)

18 (34%)

 

   Negative

55 (50%)

30 (54%)

25 (47%)

 

   Unknown

16 (15%)

6 (11%)

10 (19%)

 

Median duration of treatment (months)

9

9

9

0.73

   Range

2 - 70

2 - 59

3 - 70

 

Tamoxifen (daily dose)

   

0.17

   10 mg

1 (1%)

1 (2%)

0 (0%)

 

   20 mg

102 (94%)

50 (89%)

52 (98%)

 

   40 mg

6 (6%)

5 (9%)

1 (2%)

 

T-status, Tumor status, N-status, Lymph node status, HER2, Human Epidermal growth factor Receptor 2.

Table 2 shows that the serum concentrations of tamoxifen and its metabolites were not significantly different between pre- and postmenopausal patients. A total of 92 patients (84%) reported experiencing hot flashes during tamoxifen treatment, with considerable variation in reported hot flash severity. Of patients who reported experiencing no hot flashes before start of tamoxifen treatment, 65 (79%) reported developing hot flashes during treatment whereas all patients who reported experiencing hot flashes prior to starting tamoxifen treatment reported experiencing hot flashes during treatment. The frequency and severity of the reported hot flashes during tamoxifen treatment did not differ significantly between pre- and postmenopausal patients. For two patients, estradiol values were missing, due to an insufficient amount of input material. For 70 (64%) samples the analyzed estradiol concentration was below the lower limit of quantification (LLOQ, 43 pmol/L).
Table 2

Hot flash frequency and severity and pharmacological and biochemical parameters of study participants during treatment with tamoxifen

 

Total

Pre-menopausal

Post-menopausal

p-value

 

n = 109

n = 56

n = 53

 

n (%)

n (%)

n (%)

Pre-treatment history of hot flashes

   

0.04

   No

82 (75%)

47 (84%)

35 (66%)

 

   Yes

27 (25%)

9 (16%)

18 (34%)

 

Median frequency of hot flashes per week

21

21

21

0.77

   Range

0 - 168

0 - 168

0 - 168

 

Average severity of hot flashes

   

0.56

   None

17 (16%)

9 (16%)

8 (15%)

 

   Mild

22 (20%)

13 (23%)

9 (17%)

 

   Moderate

55 (50%)

26 (46%)

29 (55%)

 

   Severe

11 (10%)

7 (12%)

4 (8%)

 

   Very severe

4 (4%)

1 (2%)

3 (6%)

 

Median tamoxifen (ng/mL)

95.4

93.8

97.9

0.61

   Range

39.7 - 237

50.0 - 220

39.7 - 237

 

Median N-desmethyltamoxifen (ng/mL)

181

177

187

0.82

   Range

82.3 - 532

94.3 - 532

82.3 - 439

 

Median endoxifen (ng/mL)

9.12

8.59

9.16

0.75

   Range

1.73 – 22.6

1.73 – 20.3

2.14 – 22.6

 

Median 4-hydroxytamoxifen (ng/mL)

1.69

1.77

1.43

0.91

   Range

0.74 - 4.23

0.74 - 4.23

0.78 - 3.51

 

Median estradiol (pmol/L)

   

0.06

   <LLOQ*

70

33

37

 

   43.0 – 67.0

12

6

6

 

   67.0 – 361

14

8

6

 

   >361

11

9

2

 

   Missing

2

0

2

 

CYP2D6 phenotype

   

0.66

   Extensive metabolizer

54 (50%)

28 (50%)

26 (49%)

 

   Intermediate metabolizer

30 (28%)

19 (34%)

11 (21%)

 

   Poor metabolizer

5 (5%)

2 (4%)

3 (6%)

 

   Missing

20 (18%)

7 (12%)

13 (24%)

 

*<LLOQ is below the minimal quantification limit.

Genotyping

CYP2D6 genotype predicted phenotype was evaluable for 89 patients (81.7%). 5 (4.6%) patients were classified as poor metabolizers (PM), 30 (27.5%) as intermediate metabolizers (IM) and 54 (49.5%) as extensive metabolizers (EM) (see Table 2). For the other 20 patients (18.3%) the DNA quality was not sufficient to allow genotyping.

Covariate associations

Spearman’s correlation coefficients indicated a positive association between tamoxifen and its three main metabolites and a negative association between age and estradiol levels (see Additional file 2).

In addition, linear by linear tests indicated associations between CYP2D6 predicted phenotype and endoxifen (p < 0.0001), N-desmethyltamoxifen (p = 0.009) and 4-hydroxytamoxifen serum concentrations (p = 0.05), but not tamoxifen concentrations (p = 0.65) (see Additional file 3). Kruskal-Wallis tests indicated no pairwise associations between the combined menopausal and PTHF status variable and tamoxifen nor its three metabolites.

Associations with hot flashes

In the univariable Poisson and ordinal regressions no associations were found between the levels of tamoxifen, endoxifen or the two other metabolites and either the frequency or severity of hot flashes (see Table 3 and Additional file 4). When including a pairwise interaction with menopausal and PTHF status it was observed that the associations between tamoxifen and metabolite serum concentrations and the frequency of hot flashes were increasing for post-menopausal women with a pre-treatment history of hot flashes (see Table 3). Adjusting for potential confounding factors did not alter these results (Additional file 5; also see Additional file 6 for patient baseline characteristics by menopausal status and PTHF-status). Figure 1 presents the associations between serum concentrations of tamoxifen and its metabolites and patient-reported hot flash frequency in the menopausal and PTHF subgroups.
Table 3

Univariable Poisson regression associations with hot flash frequency (3A) and ordinal regression associations with hot flash severity (3B)

3A

Univariable (N = 109)

Inter.

Pre-M. (N = 56)

Post-M & PTHF (N = 18)

Post-M & no PTHF (N = 35)

 

Coef

SE

p-value

p-value

Coef

SE

p-value

Coef

SE

p-value

Coef

SE

p-value

Tamoxifen

0.002

0.0024

0.41

0.03

-0.0045

0.004

0.27

0.012

0.0038

0.01

0.0058

0.0044

0.19

N-desmethyltamoxifen

-0.00002

0.0013

0.99

0.13

-0.0013

0.002

0.50

0.0053

0.002

0.02

-0.0014

0.0031

0.66

Endoxifen

-0.015

0.022

0.50

0.01

-0.069

0.03

0.03

0.085

0.028

0.01

-0.0021

0.05

0.97

4-Hydroxytamoxifen

-0.05

0.14

0.73

0.03

-0.3

0.19

0.13

0.63

0.17

0.002

-0.056

0.37

0.88

Post-M & PTHF v pre-M

0.13

0.27

0.67

          

Post-M & no PTHF v pre-M

-0.14

0.24

           

Age

-0.0059

0.0098

0.55

          

Estradiol concentration

-0.12

0.095

0.21

          

BMI

0.048

0.023

0.04

          

Tamoxifen duration

0.084

0.087

0.34

          

CYP2D6: EM versus I/PM

-0.11

0.21

0.61

          

3B

Univariable (N = 109)

Inter.

Pre-M. (N = 56)

Post-M & PTHF (N = 18)

Post-M & no PTHF (N = 35)

 

Coef

SE

p-value

p-value

Coef

SE

p-value

Coef

SE

p-value

Coef

SE

p-value

Tamoxifen

0.0026

0.0045

0.57

0.60

0.0026

0.0065

0.69

0.018

0.014

0.16

0.0019

0.0075

0.80

N-desmethyltamoxifen

-0.00043

0.0022

0.85

0.30

-0.00048

0.003

0.88

0.01

0.0067

0.11

-0.0024

0.0039

0.53

Endoxifen

-0.013

0.039

0.73

0.72

-0.027

0.055

0.62

0.044

0.092

0.63

0.025

0.072

0.73

4-Hydroxytamoxifen

-0.20

0.25

0.43

0.64

-0.11

0.31

0.74

0.39

0.70

0.58

-0.36

0.52

0.48

Post-M & PTHF v pre-M

0.94

0.51

0.11

          

Post-M & no PTHF v pre-M

-0.17

0.42

           

Age

-0.018

0.017

0.31

          

Estradiol concentration

-0.34

0.14

0.02

          

BMI

0.19

0.048

<0.0001

          

Tamoxifen duration

0.25

0.18

0.15

          

CYP2D6: EM versus I/PM

0.0058

0.41

0.99

          

Inter, Interaction; pre-M, Pre-menopausal patients; post-M, Post-menopausal patients; PTHF, Pre-treatment hot flashes; v, Versus; Coef, Coefficient; SE, Standard error; BMI, Body mass index; EM, Extensive metabolizers; I/PM, Intermediate to poor metabolizers.

For tamoxifen and its metabolites the test of interaction with menopausal and PTHF status, and the within-group associations are also reported.

Figure 1
Figure 1

Hot-flash frequency plotted against tamoxifen and its metabolites, for pre- and post-menopausal women separately.

Positive associations were found between BMI and both hot flash frequency (p = 0.04) and severity (p < 0.0001) (Table 3A). We also observed that pre-menopausal patients with lower estradiol levels reported more severe hot flashes (p = 0.02) (Table 3B). Both of these results remained significant in the multivariable analyses (Additional file 5). The sensitivity analyses indicated that the estimated coefficients were unaffected by the imputation of the missing CYP2D6 levels. While the tests for interaction remained significant when the missing data were imputed (both as poor-intermediate and as extensive metabolizers), these tests were non-significant in the analysis excluding missing values, possibly due to the 18% reduction in sample size.

CYP2D6 predicted phenotype was not associated with hot flash frequency (p = 0.61) nor hot flash severity (p = 0.99) (Table 3).

Discussion

In this study we were unable to find evidence supporting the hypothesis that either frequency or severity of hot flashes are associated with higher levels of tamoxifen or any of its main metabolites during treatment in our entire cohort, consisting of both pre- and postmenopausal patients. No differences were detected in the frequency of reported hot flashes between pre- and post-menopausal women, however the association between concentrations of tamoxifen and its metabolites and patient-reported hot flash frequency appeared to be influenced by menopausal status and pre-treatment hot flash history.

Previously, Lorizio et al. have suggested that the endoxifen serum concentration was associated with increased risk of hot flashes, although this finding was not statistically significant [28]. Irvin et al. found no association between the extent to which patients were bothered by hot flashes and endoxifen concentration, neither at baseline, nor at four months after dose escalation [10]. We initiated this study to investigate the association of concentrations of tamoxifen and its main metabolites and both severity and frequency of hot flashes, taking potential confounding factors, such as menopausal status, pre-treatment hot flash history, duration of tamoxifen treatment, CYP2D6 phenotype, estradiol levels, age and BMI, into account. We could, however, find no evidence to support this hypothesis in the whole cohort. In the earlier mentioned BIG1-98 study, the authors also investigated hot flash incidence and the aggravation of hot flashes in the first two years of tamoxifen therapy. They found an association between CYP2D6 phenotype and tamoxifen-induced hot flashes (p = 0.02): both PM and IM phenotypes had an increased risk of tamoxifen-induced hot flashes compared with EM phenotype [13], contradictory to what was expected. Additionally, Sestak et al.[29] and Goetz et al.[30] reported that they were unable to detect an association between CYP2D6 phenotype and the occurrence of hot flashes. In this study we also found no evidence supporting the hypothesis that either hot flash frequency or severity is associated with CYP2D6 predicted phenotype, however genotyping data was missing in 18% of the cases. The large percentage of genotyping failures can be explained by the fact that DNA was isolated from serum, since this matrix was left over from the tamoxifen and metabolite analysis, which is a reproducible and validated method for genotyping in our lab, however the yield is low. Although the physiology of hot flashes, in both healthy women and women with breast cancer, remains unclear, it has been observed that healthy postmenopausal women who experience hot flashes have lower estradiol levels than women who do not experience hot flashes [3134]. In our series, we correspondingly observed that patients, especially pre-menopausal patients, with lower estradiol levels reported more severe hot flashes.

Another physiological factor that may influence the occurrence of hot flashes in healthy women is body mass index (BMI), although this relationship is still a matter of debate. Some studies found a positive association [35], others a negative association [36, 37] or no association [38]. In our series patients with higher BMIs reported suffering from more frequent and severe hot flashes.

Tamoxifen is metabolized into many different metabolites by cytochrome P450, the formation of endoxifen is mainly dependent on CYP2D6 activity. As with other studies [911], we were able to demonstrate a positive association between CYP2D6 activity and serum concentrations of active tamoxifen metabolites.

Our study has the following limitations. The hot flash data was collected retrospectively. Consequently, we are unable to completely exclude recall-bias concerning the grade and frequency of the hot flashes. Also, the modest sample size of this retrospective study requires that these results should be interpreted with care. Furthermore, only a single questionnaire was completed per patient, and as such we are unable to identify fluctuations in frequency and severity of hot flashes over the course of the tamoxifen treatment period. To adjust for any potential confounding, the duration of tamoxifen treatment was included as a covariate in the analyses. Finally, we have insufficient data concerning co-medication, other than medication to relieve hot flashes, to include this factor in our analyses, however, in the ATAC analyses medication use was not found to be an independent predictor [12].

This is the first study reporting a difference within post-menopausal patients based on their pre-treatment hot flash history in the association between tamoxifen and its main metabolite serum concentrations and hot flash frequency. This possible effect should be investigated further and requires validation in other series.

As we are unable to show that hot flash assessments are unambiguously indicative for therapeutic serum concentrations of endoxifen, and given that the value of pharmacogenomics is currently under debate, we think that future research could focus on measurement of active metabolite concentrations as a potential surrogate biomarker for tamoxifen efficacy.

Conclusions

We are unable to confirm positive associations between active tamoxifen metabolite concentrations and either the frequency or severity of hot flashes during tamoxifen treatment, when ignoring menopausal status and pre-treatment hot flash history. However, within the post-menopausal women experiencing hot flashes prior to treatment, there is evidence for positive associations between serum concentrations of tamoxifen and its metabolites with hot flash frequency.

Notes

Declarations

Acknowledgments

We thank the technical staff of the General Clinical Laboratory of the Antoni van Leeuwenhoek Hospital for DNA-isolation and estradiol measurements and Marian van Fessem for all genotyping experiments. RHTK and SCL were supported by a research grant from Pink Ribbon/A Sister’s Hope.

Authors’ Affiliations

(1)
Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands
(2)
Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
(3)
Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
(4)
Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands
(5)
Department of Clinical Chemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands
(6)
Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
(7)
Department of Pharmaceutical Sciences, Faculty of Science, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
(8)
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

References

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365 (9472): 1687-1717.View ArticleGoogle Scholar
  2. Ring A, Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004, 11 (4): 643-658. 10.1677/erc.1.00776.View ArticlePubMedGoogle Scholar
  3. Beelen K, Zwart W, Linn SC: Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nat Rev Clin Oncol. 2012, 9 (9): 529-541. 10.1038/nrclinonc.2012.121.View ArticlePubMedGoogle Scholar
  4. Lim YC, Desta Z, Flockhart DA, Skaar TC: Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005, 55 (5): 471-478. 10.1007/s00280-004-0926-7.View ArticlePubMedGoogle Scholar
  5. Johnson MD, Zuo H, Lee K-H, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004, 85 (2): 151-159. 10.1023/B:BREA.0000025406.31193.e8.View ArticlePubMedGoogle Scholar
  6. Lu WJ, Desta Z, Flockhart DA: Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat. 2012, 131 (2): 473-481. 10.1007/s10549-011-1428-z.View ArticlePubMedGoogle Scholar
  7. Teunissen SF, Rosing H, Seoane MD, Brunsveld L, Schellens JHM, Schinkel AH, Beijnen JH: Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. J Pharm Biomed Anal. 2011, 55 (3): 518-526. 10.1016/j.jpba.2011.02.009.View ArticlePubMedGoogle Scholar
  8. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, et al: Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011, 89 (5): 718-725. 10.1038/clpt.2011.32.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ: Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011, 90 (4): 605-611. 10.1038/clpt.2011.153.View ArticlePubMedGoogle Scholar
  10. Irvin WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, et al: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol. 2011, 29 (24): 3232-3239. 10.1200/JCO.2010.31.4427.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee K-H, Skaar T, Storniolo AM, Li L, Araba A, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005, 97 (1): 30-39. 10.1093/jnci/dji005.View ArticlePubMedGoogle Scholar
  12. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M, et al: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012, 104 (6): 452-460. 10.1093/jnci/djs126.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell’orto P, Biasi MO, Thürlimann B, Lyng MB, et al: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J Natl Cancer Inst. 2012, 104 (6): 441-451. 10.1093/jnci/djs125.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M: Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2012, 31 (2): 176-180.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, et al: Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011, 22 (3): 524-535. 10.1093/annonc/mdq387.View ArticlePubMedGoogle Scholar
  16. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996, 88 (21): 1529-1542. 10.1093/jnci/88.21.1529.View ArticlePubMedGoogle Scholar
  17. Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK: Tamoxifen-induced hot flashes. Clin Breast Cancer. 2000, 1 (1): 52-56. 10.3816/CBC.2000.n.004.View ArticlePubMedGoogle Scholar
  18. Love RR, Feyzi JM: Reduction in vasomotor symptoms from tamoxifen over time. J Natl Cancer Inst. 1993, 85 (8): 673-674.View ArticlePubMedGoogle Scholar
  19. Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP, WHEL Study Group: Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008, 108 (3): 421-426. 10.1007/s10549-007-9612-x.View ArticlePubMedGoogle Scholar
  20. Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists’ Group: Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008, 9 (12): 1143-1148. 10.1016/S1470-2045(08)70259-6.View ArticlePubMedGoogle Scholar
  21. Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JHM: Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011, 29 (29): 3862-3868. 10.1200/JCO.2010.33.1298.View ArticlePubMedGoogle Scholar
  22. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H: Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001, 19 (23): 4280-4290.PubMedGoogle Scholar
  23. Wet Medisch-wetenschappelijk Onderzoek met mensen - (Dutch Act on medical research involving human beings, February 26, 1998). [http://wetten.overheid.nl/BWBR0009408]
  24. Teunissen SF, Jager NGL, Rosing H, Schinkel AH, Schellens JHM, Beijnen JH: Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011, 879 (19): 1677-1685. 10.1016/j.jchromb.2011.04.011.View ArticlePubMedGoogle Scholar
  25. European_Medicines_Agency: Guideline on bioanalytical method validation. 2011, London(UK): EMEAGoogle Scholar
  26. Food_and_Drug_Administration: Bioanalytical Method Validation. 2001, Rockville, MD (USA): FDAGoogle Scholar
  27. Lammers LA, Mathijssen RHJ, van Gelder T, Bijl MJ, de Graan A-JM, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RHN: The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer. 2010, 103 (6): 765-771. 10.1038/sj.bjc.6605800.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Lorizio W, Wu AHB, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E: Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012, 132 (3): 1107-1118. 10.1007/s10549-011-1893-4.View ArticlePubMedGoogle Scholar
  29. Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J: Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol. 2006, 24 (24): 3991-3996. 10.1200/JCO.2005.04.3745.View ArticlePubMedGoogle Scholar
  30. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005, 23 (36): 9312-9318. 10.1200/JCO.2005.03.3266.View ArticlePubMedGoogle Scholar
  31. Erlik Y, Meldrum DR, Judd HL: Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol. 1982, 59 (4): 403-407.PubMedGoogle Scholar
  32. Guthrie JR, Dennerstein L, Hopper JL, Burger HG: Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet Gynecol. 1996, 88 (3): 437-442. 10.1016/0029-7844(96)00196-2.View ArticlePubMedGoogle Scholar
  33. Kronenberg F: Menopausal hot flashes: a review of physiology and biosociocultural perspective on methods of assessment. J Nutr. 2010, 140 (7): 1380S-1385S. 10.3945/jn.109.120840.View ArticlePubMedGoogle Scholar
  34. Visvanathan K, Gallicchio L, Schilling C, Babus JK, Lewis LM, Miller SR, Zacur H, Flaws JA: Cytochrome gene polymorphisms, serum estrogens, and hot flushes in midlife women. Obstet Gynecol. 2005, 106 (6): 1372-1381. 10.1097/01.AOG.0000187308.67021.98.View ArticlePubMedGoogle Scholar
  35. Moilanen J, Aalto AM, Hemminki E, Aro AR, Raitanen J, Luoto R: Prevalence of menopause symptoms and their association with lifestyle among Finnish middle-aged women. Maturitas. 2010, 67 (4): 368-374. 10.1016/j.maturitas.2010.08.007.View ArticlePubMedGoogle Scholar
  36. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR: Duration of menopausal hot flushes and associated risk factors. Obstetrics & Gynecology. 2011, 117 (5): 1095-1104. 10.1097/AOG.0b013e318214f0de.View ArticleGoogle Scholar
  37. Thurston RC, Santoro N, Matthews KA: Adiposity and hot flashes in midlife women: a modifying role of age. J Clin Endocrinol Metab. 2011, 96 (10): E1588-E1595. 10.1210/jc.2011-1082.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Gjelsvik B, Rosvold EO, Straand J, Dalen I, Hunskaar S: Symptom prevalence during menopause and factors associated with symptoms and menopausal age. Results from the Norwegian Hordaland Women’s Cohort study. Maturitas. 2011, 70 (4): 383-390. 10.1016/j.maturitas.2011.09.011.View ArticlePubMedGoogle Scholar
  39. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/612/prepub

Copyright

© Jager et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement